Lisdexamfetamine
Lisdexamfetamine Dimesylate, Vyvanse (lisdexamfetamine) is a small molecule pharmaceutical. Lisdexamfetamine was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lisdexamfetamine dimesylate | ANDA | 2025-01-30 |
| vyvanse | New Drug Application | 2023-10-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
124 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 1 | 1 | 11 | 16 | 5 | 34 |
| Hyperkinesis | D006948 | — | — | 1 | 1 | 6 | 10 | 4 | 22 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 3 | 5 | 3 | — | 11 |
| Depression | D003863 | — | F33.9 | — | 3 | 5 | 2 | — | 10 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 3 | 3 | 1 | — | 7 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 2 | 1 | 1 | 4 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | 1 | 1 | — | 2 |
| Brain injuries | D001930 | — | S06.9 | — | — | 1 | 1 | — | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 2 | — | 2 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | 1 | — | 1 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bulimia | D002032 | — | F50.2 | — | 1 | 5 | — | 1 | 7 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | 5 | — | 1 | 7 |
| Binge-eating disorder | D056912 | — | F50.2 | — | 1 | 5 | — | 1 | 7 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 4 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep deprivation | D012892 | — | F51.12 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | — | F17 | — | — | — | — | 1 | 1 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lisdexamfetamine |
| INN | lisdexamfetamine |
| Description | Lisdexamfetamine is an amino acid amide. |
| Classification | Small molecule |
| Drug class | amfetamine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN |
Identifiers
| PDB | — |
| CAS-ID | 608137-32-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201222 |
| ChEBI ID | — |
| PubChem CID | 11597698 |
| DrugBank | DB01255 |
| UNII ID | H645GUL8KJ (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
Lisdexamfetamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,068 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lisdexamfetamine dimesylate, Vyvanse
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,732 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use